Abrogation of USP9X Is a Potential Strategy to Decrease PEG10 Levels and Impede Tumor Progression in Cutaneous T-Cell...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Advanced-stage cutaneous T-cell lymphomas (CTCL) exhibit aggressive behavior and treatment resistance.
• Large-cell transformation in CTCL is driven by PEG10, but targeting it remains challenging.

Purpose of the Study:

• To investigate the post-translational regulation of PEG10 in CTCL.
• To explore USP9X as a potential therapeutic target for advanced CTCL.

Main Methods:

• Investigated the interaction between USP9X and PEG10.
• Assessed the effect of USP9X knockdown and pharmacological inhibition on PEG10 levels and CTCL cell behavior in vitro and in vivo.
• Correlated USP9X expression with patient survival data.

Main Results:

• USP9X deubiquitinates and stabilizes PEG10 in CTCL.
• USP9X inhibition downregulates PEG10, inhibits CTCL cell growth, and promotes apoptosis in vitro.
• USP9X inhibition restrains CTCL tumor growth in vivo.
• High USP9X expression correlates with poor patient survival.

Conclusions:

• USP9X is a critical regulator of PEG10 stabilization in CTCL.
• Targeting USP9X to inhibit PEG10 stabilization presents a promising therapeutic strategy for advanced-stage CTCL.